Andrew Rudd is the co-founder of Palm Therapeutics and co-inventor of DPALM technology. He performed his PhD work in the Devaraj Lab at UCSD where he developed the first small molecule approach for protein depalmitoylation. During his PhD, Andrew authored several high-impact papers and received notable awards for his scientific achievement including the Inamori Fellowship.
Neal Devaraj, co-founder of Palm, is a Professor of Chemistry and Biochemistry at the University of California, San Diego (UCSD) and co-inventor of DPALM technology. He earned his PhD in Chemistry at Stanford University in the labs of Profs. James Collman and Christopher Chidsey. After a postdoctoral fellowship at the Harvard Medical School in the lab of Prof. Ralph Weissleder, he joined UCSD. He is a world leader in bioconjugation, chemical biology, and bottom-up synthetic biology. His work has been recognized by the prestigious ACS Award in Pure Chemistry and he was recently named the 2018 Blavatnik National Laureate in Chemistry.
Neil Rudd brings over 30 years of financial management, debt and equity capital raising, strategy, mergers & acquisitions and operations expertise to Palm Therapeutics, most recently as a founder, Chief Operating Officer and Chief Financial Officer of private equity backed asset manager, NXT Capital. Prior to NXT Capital, he co-founded and served as Managing Director and Chief Operating Officer of Merrill Lynch Capital. Previously, Neil was the Senior Vice President of Corporate Strategy and Development at Heller Financial, the Director of Internal Audit at Transamerica Corporation and began his career at Price Waterhouse.
Neil earned a B.A. in Accounting from the University of Northern Iowa, an M.B.A. from the J.L. Kellogg Graduate School of Management at Northwestern University and is a CPA (inactive).
Dr. Sunkara is a seasoned CEO, accomplished scientist, serial entrepreneur and a successful angel investor. He combines over 35 years of corporate, financing, research, development and management experience in cancer, cardiovascular, CNS disease indications, molecular diagnostics and devices at Marion Merrell Dow pharmaceuticals (now Sanofi Aventis) and twelve other start up biotech and Medical Device companies in California and Michigan. Currently, he assists a number of start up biotech, medical device, and diagnostic companies through his roles as Chairman, Life Sciences investing at Tech Coast Angels, Board Member and Advisor.
Peter Chu is a scientist-turned-entrepreneur, biotech executive and investor who has spent the last 15+ years on both the research and executive management side of small, medium and large biotech companies. He was the founding CEO of Eclipse Therapeutics, a Biogen Idec (NASDAQ:BIIB) spinout that was acquired by Bionomics Ltd (BNO:ASX), where he led development of the cancer stem cell antibody BNC101 from conception through to human clinical trials in colon cancer. He is a board director at Echo Laboratories.
Robert J. Ternansky, Ph.D. is an experienced medicinal chemist and currently serves as Senior Director of Translational Chemistry at Retrophin, Inc. and Lecturer at the University of California, San Diego. Dr. Ternansky was previously the Senior Vice President of Chemistry at Attenuon, LLC where he led the chemistry efforts that resulted in the advancement of two compounds through Phase II clinical trials in cancer. Prior to Attenuon, Dr. Ternansky served as Director of Medicinal Chemistry at IDUN Pharmaceuticals, Inc. in San Diego where he co-invented a lead series of caspase inhibitors for the prevention of apoptotic cell death. Prior to his work at IDUN, Dr. Ternansky held the position of Associate Director of Inflammation at La Jolla Pharmaceuticals, Inc., where he led the analytical team on the pre-clinical development of LJP-394, a toleragen for the treatment of lupus, currently in Phase III trials. Prior to joining La Jolla Pharmaceuticals, Dr. Ternansky was a Research Scientist and Team Leader at Eli Lilly and Co., where he invented LY193239, the first pyrazolidinone antibacterial agent to be developed for clinical investigation. He was also a member of the pre-clinical discovery/development team for loracarbef (Lorabid), the first marketed 1-carbacephalosporin antibacterial agent. Finally, Dr. Ternansky is a co-inventor of trovirdine, a NNRT inhibitor of HIV-1 RT, which progressed through Phase II trials for the treatment of HIV infection. Dr. Ternansky received his Ph.D. in Synthetic Organic Chemistry from The Ohio State University under the direction of Professor Leo A. Paquette and completed his post-doctoral training with Professor Paul A. Wender at Stanford University.
Copyright © 2018-2020 Palm Therapeutics - All Rights Reserved.